Systemic lupus erythematosus.
Systemic lupus erythematosus (SLE) is the most common of the connective tissue disorders and can involve virtually any organ in the body. It is associated with pleuropulmonary manifestations in well over 50% of cases. Pleuritis with or without pleural effusion is the most common manifestation and can be particularly troublesome to manage but is rarely life-threatening. More serious manifestations in the lung include acute lupus pneumonitis with or without alveolar haemorrhage, chronic lupus pneumonitis and pulmonary hypertension. These all contribute significantly to overall mortality in SLE. The association between SLE and the antiphospholipid syndrome, leading to venous thrombosis and pulmonary embolism, is well recognized. Up to 20% of all cases of SLE present in childhood and many of these have pulmonary features at presentation or during the course of their illness. Sepsis is one of the main causes of death in SLE and pulmonary sepsis in these often immunocompromised patients contributes a significant proportion. Several drugs can produce a clinical syndrome that has many of the clinical and immunological features of SLE. Pleuritis may be seen in up to half of these cases of drug induced SLE. The development of SLE and conditions such as sarcoidosis or asbestosis in the same patient may represent a simple coincidence but there is some evidence for a closer association between these disorders.
University College Dublin, St Vincent's Hospital, Dublin, Ireland.
D
D
Mulherin
B
B
Bresnihan
D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology; D008171:Lung Diseases / Q000209:etiology; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D010995:Pleural Diseases / Q000209:etiology; D012140:Respiratory Tract Diseases / Q000209:etiology*